Business Development Solutions
AI-powered asset evaluation and competitive intelligence for pharma BD teams
Software · Cloud SaaSCompany source
Company profile
About QuantHealth
QuantHealth is a clinical AI company that has developed a next-generation platform for simulating clinical trial outcomes before they are conducted. The company's proprietary technology combines a comprehensive biomedical knowledge graph with real-world data from over 350 million patient lives to create digital twins and digital drugs that can predict how any patient will respond to any therapy. QuantHealth's platform supports pharmaceutical sponsors across the entire clinical development lifecycle, from early protocol optimization and indication selection to business development and portfolio management. The company's AI models have demonstrated 85% accuracy in predicting primary endpoints prospectively, without requiring sponsor data. By simulating thousands of protocol variations in parallel, QuantHealth enables sponsors to optimize trial design, reduce enrollment time, minimize patient numbers, and improve probability of technical success. The platform integrates multi-modal data including biomedical knowledge, clinical trial results, and epidemiological information, with over 10,000 data points per patient spanning more than 10 years of medical history. QuantHealth serves pharmaceutical companies across multiple therapeutic areas including oncology, respiratory disease, metabolic disorders, and inflammatory conditions, helping them make data-driven decisions that reduce costs and accelerate time to market.
Company description QuantHealth official website
Primary marketClinical Trials & Research
Commercial modelCommercial information available on request
Work at QuantHealth?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Acute Respiratory Disease
- Head & Neck Cancer
- Inflammatory Bowel Disease
- MASH (Metabolic dysfunction-associated steatohepatitis)
- Metabolism and Endocrinology disorders
- Multiple Myeloma
- Oncology (various)
Who it serves
- Biotechnology companies
- Clinical development teams
- Clinical operations teams
- Data science teams
- Pharmaceutical sponsors
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsGlobal pharmaceutical market · Israel · United States
Company sourceOfficial website
Company milestones
Platform expansion
Over 350 trials simulated, 85% endpoint prediction accuracy achieved, multiple case studies published demonstrating value across therapeutic areas (2023-2024)
Partnerships
Recorded partners
No partners are currently listed.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Clinical Development Solutions
Protocol optimization and trial design tools for clinical development teams
Software · Cloud SaaSCompany source
Portfolio Management Solutions
Portfolio optimization tools for pharmaceutical asset prioritization
Software · Cloud SaaSCompany source
QuantHealth Clinical Simulation Platform
AI-powered clinical trial simulation platform predicting patient responses to therapies
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
85% accuracy on primary endpoint prediction
Prospective validation without sponsor data
$15M operational savings
Reduced enrollment time and site monitoring costs in respiratory disease trial
$200M incremental peak sales
Earlier launch due to optimized trial design
11 months reduction in enrollment time
Acute respiratory disease case study
251 fewer patients required
Protocol optimization in respiratory trial
$256M value creation
Salvaging phase 3 trial in HNSCC
$146M incremental return
8 months reduced time to market in oncology
140 fewer patients, $8.88M savings
Dose optimization in metabolism/endocrinology phase 2b
9.3 months trial length reduction
Reduced arms from 4 to 2 in phase 2b
Pharmaceutical Sponsor - Head & Neck Cancer
Phase 3 protocol optimization for novel antibody-drug conjugate (ADC) in metastatic HNSCC
$256M value from salvaging phase 3 trial, $146M from 8-month reduction in time to market, improved probability of hitting 3-month OS improvement at interim analysis
Pharmaceutical Sponsor - MASH (Metabolism and Endocrinology)
Phase 2b trial design optimization combining AI-driven clinical optimization with population PK-PD modeling for novel therapeutic
140 fewer patients needed ($8.88M savings), 9.3-month reduction in trial length, $141M value from reduced time to market, reduced trial arms from 4 to 2
Pharmaceutical Sponsor - Acute Respiratory Disease
Clinical trial protocol optimization for acute respiratory disease within 9-month timeline and reduced budget
11-month reduction in enrollment time, 251 fewer subjects needed, $15M savings in site monitoring costs, ~$200M in projected peak sales from earlier launch, $385K savings in protocol design FTE
Pharmaceutical Sponsor - Inflammatory Bowel Disease
AI-based clinical prioritization of portfolio assets for inflammatory bowel disease
Portfolio prioritization to maximize clinical trial success
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Omri Matalon
VP Clinical Data Science
06 · Company updates
Updates from QuantHealth
Recent articles published on QuantHealth's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Clinical Trials & Research
Companies using AI to optimize clinical trial design, accelerate patient recruitment, match patients to trials, predict trial outcomes, or improve clinical research efficiency. Includes patient enrollment and screening platforms, AI-powered trial matching, and tools that reduce the time and cost of bringing new treatments to market.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.